New combo therapy fights tough liver cancer
NCT ID NCT06631326
Summary
This study compared two treatment approaches for advanced liver cancer that had spread into a major vein. Researchers tested whether adding a targeted liver chemotherapy (HAIC) to standard drug therapy (lenvatinib and PD-1 inhibitors) worked better than the standard drugs alone. The trial involved 244 patients with this aggressive form of cancer to see which combination helped people live longer and kept the cancer from growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The first hospital of China medical university
Shenyang, Liaoning, 110000, China
Conditions
Explore the condition pages connected to this study.